The Artemis/ProFuse platform offers several benefits for prostate cancer diagnosis and treatment. It provides accurate and selective prostatic biopsies, reducing the number of biopsies required and minimizing the side effects of the investigation. For men with suspicious lesions (Pirad 4 or 5), the platform allows for fewer biopsies while maintaining high detection accuracy. Furthermore, the platform’s ability to record the exact placement of positive samples enables urologists to perform additional biopsies in the same spot over time, aiding in monitoring cancer characteristics and facilitating active surveillance.
FAQS